These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 21897063)

  • 1. [Current status in and future directions of the treatment of hematological disorders with molecular-targeting agents--Overview].
    Kizaki M
    Rinsho Ketsueki; 2011 Aug; 52(8):583-6. PubMed ID: 21897063
    [No Abstract]   [Full Text] [Related]  

  • 2. Eculizumab (Soliris) for paroxysmal nocturnal hemoglobinuria.
    Med Lett Drugs Ther; 2007 Sep; 49(1270):79-80. PubMed ID: 17878890
    [No Abstract]   [Full Text] [Related]  

  • 3. [Programs for continuing medical education: B session 7. Progress in treatment for hematologic diseases].
    Higashihara M
    Nihon Naika Gakkai Zasshi; 2014 Mar; 103(3):717-23. PubMed ID: 24796142
    [No Abstract]   [Full Text] [Related]  

  • 4. [Development and clinical application of novel proteasome inhibitors].
    Iida S
    Rinsho Ketsueki; 2012 Apr; 53(4):417-25. PubMed ID: 22687975
    [No Abstract]   [Full Text] [Related]  

  • 5. [Feature articles: current status and future direction of the treatment of hematological disorders with molecular-targeting agents (1)].
    Kizaki M
    Rinsho Ketsueki; 2011 Jul; 52(7):433-7. PubMed ID: 21821973
    [No Abstract]   [Full Text] [Related]  

  • 6. Severe pancytopenia associated with a minor paroxysmal nocturnal haemoglobinuria clone and response to ciclosporin A in a heavily pretreated multiple myeloma patient.
    Kulagin A; Lisukov I; Denisova V; Kruchkova I; Sizikova S; Gilevich A; Pronkina N; Kozhevnikov V; Kozlov V
    Br J Haematol; 2008 Apr; 141(1):122-3. PubMed ID: 18279453
    [No Abstract]   [Full Text] [Related]  

  • 7. [Current treatment strategies with novel agents for multiple myeloma].
    Tokuhira M
    Rinsho Ketsueki; 2011 Aug; 52(8):587-602. PubMed ID: 21897064
    [No Abstract]   [Full Text] [Related]  

  • 8. [Current status and future perspective of new drugs for hematological malignancies in Japan].
    Ogura M
    Rinsho Ketsueki; 2007 Oct; 48(10):1442-52. PubMed ID: 17933133
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].
    Tobinai K
    Rinsho Ketsueki; 2007 Jun; 48(6):451-7. PubMed ID: 17633092
    [No Abstract]   [Full Text] [Related]  

  • 10. Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria. Reply.
    Risitano AM; Kulasekararaj AG; Peffault de Latour R
    N Engl J Med; 2024 Jun; 390(21):2033-2034. PubMed ID: 38838321
    [No Abstract]   [Full Text] [Related]  

  • 11. Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria.
    Marnas P; Zarogiannis SG
    N Engl J Med; 2024 Jun; 390(21):2033. PubMed ID: 38838320
    [No Abstract]   [Full Text] [Related]  

  • 12. Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria.
    Hillmen P
    N Engl J Med; 2024 Jun; 390(21):2032-2033. PubMed ID: 38838319
    [No Abstract]   [Full Text] [Related]  

  • 13. New treatment options for immune-mediated hematological disorders.
    Dierickx D; De Rycke A; Vanderschueren S; Delannoy A
    Eur J Intern Med; 2008 Dec; 19(8):579-86. PubMed ID: 19046722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphoma study group of JCOG.
    Tsukasaki K; Tobinai K; Hotta T; Shimoyama M
    Jpn J Clin Oncol; 2012 Feb; 42(2):85-95. PubMed ID: 22147803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emotional consequences of corticosteroid use in hematology: preliminary findings.
    McGrath P; Holewa H
    J Psychosoc Oncol; 2010; 28(4):335-50. PubMed ID: 20623411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Interferons in the treatment of hematological diseases].
    Jantunen E; Nousiainen T
    Duodecim; 1998; 114(12):1240-7. PubMed ID: 11524770
    [No Abstract]   [Full Text] [Related]  

  • 17. Low dose cepharanthine ameliorates immune thrombocytopenic purpura associated with multiple myeloma.
    Tabata R; Tabata C; Tazoh A; Nagai T
    Int Immunopharmacol; 2012 Jul; 13(3):242-4. PubMed ID: 22561120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Wnt pathway in lymphoma and myeloma cells.
    Schmidt M; Sievers E; Endo T; Lu D; Carson D; Schmidt-Wolf IG
    Br J Haematol; 2009 Mar; 144(5):796-8. PubMed ID: 19036118
    [No Abstract]   [Full Text] [Related]  

  • 19. Battling the hematological malignancies: the 200 years' war.
    Lichtman MA
    Oncologist; 2008 Feb; 13(2):126-38. PubMed ID: 18305057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current trends in chemotherapy of leukaemias lymphomas and multiple myeloma.
    Kasili EG
    East Afr Med J; 1976 Sep; 53(9):554-9. PubMed ID: 1009883
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.